Monitoring Drug and Antidrug Levels: A Rational Approach in Rheumatoid Arthritis Patients Treated with Biologic Agents Who Experience Inadequate Response While Being on a Stable Biologic Treatment

Table 3

Patient's characteristics among positive and negative anti-IFX antibodies.

	Positive anti-IFX antibodies	Negative anti-IFX antibodies	𝑃 value
Disease duration, mean, and months	90.77±49.56	128±97.48	0.306
IFX treatment duration, mean, and months	29.77±17.01	38.77±34.60	0.511
DAS28 at flare and mean	5.09±1.19	4.18±1.67	0.189
DAS28 after 2 months and mean	5.68±0.8	3.95±1.49	0.006
csDMARD association and nr (%)	3	9	0.028

Differences between patient's characteristics were tested by Student’s 𝑡-test or chi-square test.
IFX: infliximab; csDMARD: conventional synthetic disease modifying antirheumatic drug.